| 2003D-0206 - Draft Guidance for Industry on Exocrine Pancreatic Insufficiency Drug Products--Submitting New Drug Application; Availability | |||||||||||||||||||||||
| FDA Comment Number : | EC1 | ||||||||||||||||||||||
| Submitter : | Dr. Drucy Borowitz | Date & Time: | 06/10/2004 05:06:15 | ||||||||||||||||||||
| Organization : | Women and Children's Hospital of Buffalo | ||||||||||||||||||||||
| Health Professional | |||||||||||||||||||||||
| Category : | |||||||||||||||||||||||
| Issue Areas/Comments | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| Our article is misquoted (page 7, lines 283 and 284; reference on page 10 line 388). We recommend starting dose titration at 500-1000 lipase units/kg/meal. The maximum enzyme dose should be 2500 lipase units/kg/meal, NOT 6,000. It is very important to correct this error. | |||||||||||||||||||||||